Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, December 9 at 2:00 PM ET

Register Free →

Sanger DNA Sequencing and Sample Processing

Open
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Durham, NC, 27709, USA

Set-Aside

NONE

Documents

This scope was carved out of 75N98027Q00090.

The full solicitation package (2 documents), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

DNA Sequencing Service

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Due in 20 days

Read the full solicitation package

This scope is part of a larger contract. Its documents live on the prime.

  • 2 documents on the prime contractFrom DNA Sequencing Service
Read the prime's documents

Ask CLEATUS

I've read this contract. Ask me anything.

Timeline

Posted

subcontract

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health Olao
ContactsNo contacts available
OfficeN/A
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Performs high-throughput Sanger DNA sequencing for prime contractors on NIH/NIEHS projects. Processes plasmid DNA, genomic DNA, and PCR-generated material via PCR amplification, product purification, and DNA normalization. Utilizes automated Sanger sequencing instrumentation and QA/QC procedures for reproducible results. Delivers electronic sequencing data in .ab1, .seq, .scf, .phd.1, .txt, and .fasta/.fa formats.

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Federal
Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)
Solicitation # W911SR-26-R-HEAL
The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) is establishing the Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) ecosystem. This continuous, open announcement seeks to build a network of pre-qualified partners to accelerate the development, testing, and fielding of next-generation medical defense solutions. The program focuses on two primary pillars: host-targeted resilience, which targets critical host systems like neurological and respiratory pathways to enhance physiological protection, and threat-targeted neutralization, which focuses on broad-spectrum countermeasures for prophylaxis and acute treatment. Priority is given to candidates designed for austere environments, featuring environmental stability without cold-chain reliance and simplified administration routes such as oral or intranasal delivery. The government is inviting two types of participants: MCM Development Collaborators, ranging from Phase I products through FDA licensure, and MCM Development Support Collaborators, such as CROs and CDMOs specializing in preclinical testing, cGMP manufacturing, and regulatory submissions. Interested parties must submit a white paper of no more than five pages detailing their product descriptions, efficacy data, regulatory status, and manufacturing capabilities. Acceptance into the PBA enables the subsequent award of project orders under the authority of 10 U.S.C sections 4021, 4022, and 4023. These agreements are not subject to the Competition in Contracting Act of 1984. All prospective awardees must be registered in the System for Award Management (SAM) database to receive payment.
W6QK Acc-Apg

POSTED

about 12 hours ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Federal
DNA Sequencing Service
Solicitation # 75N98027Q00090
The National Institutes of Health (NIH) is soliciting a Firm Fixed-Price Indefinite Delivery/Indefinite Quantity (IDIQ) contract for high-throughput DNA sequencing services, including Sanger DNA sequencing and whole-plasmid sequencing. The scope of work involves processing plasmid DNA, genomic DNA, and PCR-generated material, with requirements for PCR amplification, product purification, and DNA normalization. The contractor is responsible for providing all sample collection and shipping materials, maintaining strict confidentiality of sequencing data, and retaining DNA samples for at least 180 days post-sequencing. Deliverables include specific electronic file formats such as .ab1, .fasta, and raw FASTQ data, alongside a Monthly Status Report submitted to the Contracting Officer's Representative (COR). The contract spans a five-year period from January 4, 2027, to January 3, 2032, with a total estimated value ranging from $184,200.00 to $958,584.20. Performance and delivery are centered at the NIEHS facility in Research Triangle Park, North Carolina. Award selection will be based on a best value tradeoff, where technical capability and past performance are weighted more heavily than price. Technical evaluations will focus on sequencing capability, personnel qualifications, quality assurance/control, and data management. The acquisition is not set aside for small businesses and falls under NAICS code 541714.
National Institutes Of Health Olao

POSTED

about 12 hours ago

DEADLINE

in 20 days
View Details
NAICS: 541714
New
Federal
FY27 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
Solicitation # FDABAA-27-00123
The FY27 FDA Broad Agency Announcement (FDABAA-27-00123) solicits basic and applied research and development proposals to advance regulatory science and innovation. Managed by the FDA Office of Acquisitions and Grants Services, this solicitation is open to all responsible sources, including small businesses and academic institutions. The program focuses on 22 priority research areas, with recent updates adding specific interests in human tooth enamel evaluation techniques for anticaries dentifrice products and the adoption of Super Intelligence terminology in tobacco and nicotine research per Executive Order 14434. Interested parties must follow a two-tiered submission process consisting of a three-page concept paper and a comprehensive full proposal, which includes a technical volume limited to 50 pages and a detailed cost proposal. All applications must be submitted as searchable PDFs via email by January 22, 2027, at 5:00 PM EST. A virtual BAA Day is scheduled for December 8, 2026, to provide guidance on the application process and FDA priorities. Awards are based on the overall best value to the government, evaluated through a high-level relevance review followed by a technical review by subject matter experts. Successful offerors must comply with Good Manufacturing Practice Regulations (21 CFR Parts 210-211) and other relevant biological or diagnostic standards. Additionally, proposals exceeding $900,000 from non-small businesses require a Small Business Subcontracting Plan. Contractors must also warrant the absence of organizational conflicts of interest and adhere to strict data disclosure and privacy regulations.
FDA Office Of Acq Grant Svcs

POSTED

1 day ago

DEADLINE

in 2 months
View Details
NAICS: 541714
New
Federal
Presolicitation Notice to Sole Source for Experimental Pathology Laboratories, Inc. (EPL)
Solicitation # Presolicitation_NOI_Sole_Source_EPL
The U.S. Environmental Protection Agency, through the Office of the Chief Procurement Officer's Water, Tribal, and Science Division, intends to award a firm-fixed price purchase order for histology and pathology services of maternal and neonatal rodent specimen organs. The work will be performed at the EPA Headquarters in Washington, DC, and focuses on the toxicologic pathology of environmental contaminants, including PFAS, phthalates, air pollutants, and endocrine-disrupting compounds. This acquisition is intended to continue existing larger studies to maintain data integrity and avoid protocol deviations. The EPA intends to sole source this requirement to Experimental Pathology Laboratories, Inc. (EPL) due to their specialized experience with environmental contaminants, compliance with Good Laboratory Practice regulations, and their ability to accept hand-delivered samples as a local vendor. The procurement falls under NAICS code 541714 for Research and Development in Biotechnology and PSC code AZ11. While the agency intends to award to EPL, other responsible sources may submit capability statements, proposals, or quotations by November 30, 2026. The estimated award date is December 3, 2026. All vendors must maintain a public profile in the System for Award Management and utilize the FedConnect portal for contract communications.
Tribal & Science Division Water

POSTED

4 days ago

DEADLINE

in 13 days
View Details
NAICS: 541714
New
Federal
Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS)
Solicitation # ARPA-H-SOL-26-164
The Advanced Research Projects Agency for Health (ARPA-H) is soliciting proposals for the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program under solicitation ARPA-H-SOL-26-164. This five-year initiative aims to create a reusable blueprint for future adaptive seamless platform trials through the integration of three technical areas: a Phaseless Design Engine, Continuous Inference, and Agentic Operations. The program is divided into two stages, with Stage I focusing on capability buildout, FDA engagement, and the onboarding of at least three intervention arms over 24 months, followed by a 36-month Stage II dedicated to validation and deployment. A critical go/no-go milestone is obtaining FDA authorization for the platform Master Protocol IND and at least one investigational arm by the end of Stage I. The government intends to make multiple awards via Other Transaction Agreements to proposers offering the most advantageous solutions based on innovation, feasibility, and technical merit at reasonable prices. Eligible entities must possess a Unique Entity Identifier and active SAM registration. Proposals are submitted in a phased approach, beginning with a Solution Summary and potentially progressing to a Solution Pitch package. Performance will be measured by the successful integration of the three technical areas and the achievement of specific program metrics. All work must adhere to ICH E6(R3) Good Clinical Practice and strict regulatory standards to ensure inspection readiness and participant safety.
Advanced Research Projects Agency For Health (arpa-H)

POSTED

4 days ago

DEADLINE

in 13 days
View Details

More opportunities from Department Of Health And Human Services → National Institutes Of Health Olao

Same awarding agency

NAICS: 334516
New
Federal
Combined Synopsis Solicitation (competitive)
Solicitation # 75N98027Q00093
The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, is seeking a firm fix-price contract for the acquisition of sequencing kits under solicitation 75N98027Q00093/PCA-NIA-11864. This competitive procurement is for commercial items and is not a small business set-aside, meaning the requirement is unrestricted. The scope of work includes the procurement of 114 units of cDNA-PCR Sequencing Kit V14 (SQK-PCS114) and 171 units of PromethION Flow Cells Packs DNA (FLO-PRO114M). Technical requirements specify that flow cells must be compatible with Nanopore PromethION 48 sequencers and generate consensus data with a modal accuracy above 99%, while the cDNA-PCR kits must support six reactions and require no more than 10 ng poly(A)+ RNA or 500 ng total RNA as starting material. Award will be based on the best value to the Government, evaluating factors such as price, technical capability, past performance, and delivery schedule. Deliveries are to be made to NIH/NIA in Baltimore, Maryland, and all items must be packaged and marked according to Government specifications, including the contract number and contractor name. Offerors must be registered in the System for Award Management (SAM) and provide their Unique Entity Identifier (UEI), Taxpayer Identification Number (TIN), business size certification, and a completed FAR 52.212-3 representation and certification. Proposals must include unit and total pricing, shipping and handling costs, and a delivery timeframe after award.
Analytical Laboratory Instrument Manufacturing

POSTED

about 12 hours ago

DEADLINE

in 17 days
View Details
NAICS: 334510
New
Federal
NCSS - Sentec tCOM+ Transcutaneous CO2 Monitor Acq
Solicitation # 75N98027Q00094
The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to award a non-competitive, firm-fixed-price purchase order to Sentec Inc. for the acquisition of a Sentec tCOM+ transcutaneous CO2 (tcPCO2) monitor with V-sign Sensor 2. This equipment is required for the National Heart, Lung, and Blood Institute (NHLBI) Pulmonary Function Testing Laboratory to perform cardiopulmonary exercise testing (CPET). The system provides continuous, non-invasive monitoring of transcutaneous CO2, oxygen saturation, and pulse rate, which is critical for maintaining clinical standardization and longitudinal data continuity across ongoing research protocols. The scope of work includes the delivery of the hardware, on-site installation at the NIH Clinical Research Center in Bethesda, Maryland, technical support, and clinical staff education. This acquisition is conducted under the authority of FAR 12.603 for streamlined solicitation of commercial products and is not expected to exceed the simplified acquisition threshold. As Sentec Inc. is the original equipment manufacturer and sole distributor, the procurement is being handled on a non-competitive basis. The solicitation, numbered 75N98027Q00094, falls under NAICS code 334510 and is not set aside for small business. All invoices must be processed through the Invoicing Processing Platform using a three-way match. Responses are due by November 27, 2026, and must include a Unique Entity Identifier, Taxpayer Identification Number, and business size certification.
Electromedical and Electrotherapeutic Apparatus Manufacturing

POSTED

about 12 hours ago

DEADLINE

in 10 days
View Details

Get AI-powered intelligence on this solicitation and the ones like it

Every solicitation package arrives shredded into a compliance breakdown and matched to your past performance, with incumbent history and alerts on amendments and award.

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS